Tag: Astrazeneca
Cellectis: Signature of the definitive agreement with AstraZeneca
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
AstraZeneca prioritizes US for its RSV drug due to rising cases – 11/10/2023 at 8:18 p.m.
by Patrick Wingrove and Maggie Fick AstraZeneca AZN.L said on Friday it was prioritizing the U.S. market for additional doses of its respiratory syncytial virus (RSV) drug Beyfortus, which was…
AstraZeneca: exclusive licensing agreement with Eccogene
(CercleFinance.com) – AstraZeneca announces that it has entered into an exclusive licensing agreement with Eccogene for ‘ECC5004’, an experimental daily oral treatment aimed at combating obesity, type 2 diabetes and…
AstraZeneca: encouraging results in liver cancer
(CercleFinance.com) – AstraZeneca announces that the results of a phase III trial showed that Imfinzi (durvalumab), combined with transarterial chemoembolization (TACE, a therapy for the treatment of liver cancer) and…
AstraZeneca: positive results around Lokelma
(CercleFinance.com) – AstraZeneca announces that the results of a multi-country observational study presented today at the American Society of Nephrology (ASN) show that the treatment of hyperkalemia (HK) with the…
AstraZeneca invests in Cellectis – 01/11/2023 at 08:58
(AOF) – Cellectis has entered into a research collaboration agreement with AstraZeneca, an investment agreement for an initial investment of $80 million and a memorandum of understanding for a possible…
Cellectis: the title soars, alliance with AstraZeneca – 01/11/2023 at 09:49
(CercleFinance.com) – Cellectis soars on the Paris Stock Exchange on Wednesday after unveiling a strategic collaboration with the pharmaceutical giant AstraZeneca, which will allow the latter to take a 22%…
Immunology and oncology: AstraZeneca signs an agreement with the French Cellectis – 01/11/2023 at 11:24
The British pharmaceutical giant AstraZeneca announced on Wednesday “a collaboration and investment agreement with Cellectis”, a French biotechnology company, which should enable the development of new products “in immunology, oncology…
AstraZeneca: Positive data in endometrial cancer
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
AstraZeneca: Encouraging results for Tagrisso
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
AstraZeneca: encouraging results for Tagrisso
(CercleFinance.com) – AstraZeneca announced that results from a phase III trial showed that Tagrisso (osimertinib) combined with chemotherapy demonstrated a 42% improvement in central nervous system progression-free survival (PFS) (…
AstraZeneca: positive results in gastric cancers
(CercleFinance.com) – AstraZeneca reported on Friday positive preliminary results from a phase III clinical study in the treatment of stomach and gastric junction cancers. According to these data, its Imfinzi…